
Reveal Cellular Choreography, See Biology in Motion
Cellanome is a biotechnology company reimagining how scientists study living cells. Unlike traditional tools that only capture static snapshots, Cellanome's live-cell analysis platform enables researchers to observe cells in action — tracking behavior, interactions, and molecular changes over time. At the core of the platform is CellCage technology, a micro-3D printed system that creates customizable, biocompatible microenvironments for isolating single cells or small groups. CellCage enclosures allow scientists to culture, perturb, and monitor cells in real time, then connect those live observations to downstream molecular data including transcriptomics. By integrating time-lapse imaging with single-cell molecular profiling, Cellanome generates structured, longitudinal, multimodal datasets that provide the context AI systems need to uncover disease mechanisms, identify therapeutic targets, and accelerate drug discovery. The platform supports research applications in oncology, immunology, neuroscience, and aging and metabolic disease. Led by pioneers in life sciences and backed by top-tier investors including DFJ Growth, Cellanome is partnering with leading academic labs and biopharma companies to build the data infrastructure biology has been missing.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free AccountAI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...

Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
BridgeBio makes targeted treatments for genetic diseases.